COVID-19 Induced Miller Fisher Syndrome Presenting With Autonomic Dysfunction: A Unique Case Report and Review of Literature

Biswas, Subhrajyoti; Ghosh, Ritwik; Mandal, Arpan; Pandit, Alak; Roy, Dipayan; Sengupta, Samya; De, Kaustav; Swaika, Bikash Chandra; Benito‐León, Julián

doi:10.1177/19418744211016709

Cited by 21 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The case we describe is an unusual initial presentation of COVID-19 manifesting as MFS. The writers of this article did a Medline and PubMed Search and found that there are only twelve other cases of COVID-19induced MFS [4][5][6][7][8][9][10][11][12][13][14][15]. We compared the findings in our study with the other studies for presentation, antibodies, MRI findings, and recurrence.…”

Section: Discussionmentioning

confidence: 95%

“…Although it is not uncommon for COVID 19 to present with neurological manifestations, Miller Fisher syndrome (MFS), a rare variant of Guillain-Barré syndrome (GBS), secondary to COVID-19, has only been reported a handful of times in the literature [4][5][6][7][8][9][10][11][12][13][14][15]. Here we report a unique case of coronavirus disease 19 presenting as Miller Fisher syndrome with positive anti-GQ1b antibodies in a patient with a history of Guillain-Barré syndrome.…”

Section: Introductionmentioning

confidence: 93%

See 1 more Smart Citation

COVID-19 Presenting As Miller Fisher Syndrome in a Patient With a History of Guillain-Barré Syndrome: A Case Report

Aldabain¹,

Haddaden²,

Farooqi³

et al. 2022

Cureus

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 93%

COVID-19 Presenting As Miller Fisher Syndrome in a Patient With a History of Guillain-Barré Syndrome: A Case Report

Aldabain¹,

Haddaden²,

Farooqi³

et al. 2022

Cureus

View full text Add to dashboard Cite

“…It is speculated that the pathogenesis of Miller Fisher syndrome following SARS-CoV-2 infection is mediated by neurotropism or aberrant activation of the immune system, with production of circulating antibodies similar to GDq1B in idiopathic Miller Fisher syndrome ( 42 ).…”

Section: The Role Of Dysautonomia In the Clinical Course Of Covid-19mentioning

confidence: 99%

Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies

et al. 2022

View full text Add to dashboard Cite

IntroductionOn March 11, 2020, the World Health Organization sounded the COVID-19 pandemic alarm. While efforts in the first few months focused on reducing the mortality of infected patients, there is increasing data on the effects of long-term infection (Post-COVID-19 condition). Among the different symptoms described after acute infection, those derived from autonomic dysfunction are especially frequent and limiting.ObjectiveTo conduct a narrative review synthesizing current evidence of the signs and symptoms of dysautonomia in patients diagnosed with COVID-19, together with a compilation of available treatment guidelines.ResultsAutonomic dysfunction associated with SARS-CoV-2 infection occurs at different temporal stages. Some of the proposed pathophysiological mechanisms include direct tissue damage, immune dysregulation, hormonal disturbances, elevated cytokine levels, and persistent low-grade infection. Acute autonomic dysfunction has a direct impact on the mortality risk, given its repercussions on the respiratory, cardiovascular, and neurological systems. Iatrogenic autonomic dysfunction is a side effect caused by the drugs used and/or admission to the intensive care unit. Finally, late dysautonomia occurs in 2.5% of patients with Post-COVID-19 condition. While orthostatic hypotension and neurally-mediated syncope should be considered, postural orthostatic tachycardia syndrome (POTS) appears to be the most common autonomic phenotype among these patients. A review of diagnostic and treatment guidelines focused on each type of dysautonomic condition was done.ConclusionSymptoms deriving from autonomic dysfunction involvement are common in those affected by COVID-19. These symptoms have a great impact on the quality of life both in the short and medium to long term. A better understanding of the pathophysiological mechanisms of Post-COVID manifestations that affect the autonomic nervous system, and targeted therapeutic management could help reduce the sequelae of COVID-19, especially if we act in the earliest phases of the disease.

show abstract

“…There have been several cases describing post-COVID-19 Miller Fisher syndrome, and they all presented similar symptoms and evolution [ 95 , 96 , 97 , 98 , 99 , 100 , 101 ]. Neurological symptoms were usually observed 5–20 days after the COVID-19 diagnosis [ 95 , 96 , 97 , 98 , 99 , 100 , 101 ]. The most common symptoms related to MFS included paresthesia, ophthalmoplegia, blurred vision, ataxia, areflexia, and others.…”

Section: Othermentioning

confidence: 99%

“…According to the studies, most patients have responded well to intravenous immunoglobulin [ 95 ]. Of note, post-COVID-19 MFS was also reported in a 7-year-old child [ 98 ].…”

Section: Othermentioning

confidence: 99%

How Does SARS-CoV-2 Affect Our Eyes—What Have We Learnt So Far about the Ophthalmic Manifestations of COVID-19?

Baj

Forma

Teresińska

et al. 2022

JCM

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has become a worldwide threat resulting in a pandemic in 2020. SARS-CoV-2 infection manifests itself as coronavirus disease 2019 (COVID-19) that is evidenced in a vast number of either specific or nonspecific symptoms. Except for typical (but nonspecific) symptoms such as fever, dry cough, or muscle weakness, the infected patients might also present atypical symptoms including neurological, dermatological, or ophthalmic manifestations. This paper summarizes the current state of knowledge regarding the onset, progression, and types of ophthalmic symptoms induced by SARS-CoV-2 infection recognized amongst the infected patients.

show abstract

COVID-19 Induced Miller Fisher Syndrome Presenting With Autonomic Dysfunction: A Unique Case Report and Review of Literature

Cited by 21 publications

References 20 publications

COVID-19 Presenting As Miller Fisher Syndrome in a Patient With a History of Guillain-Barré Syndrome: A Case Report

COVID-19 Presenting As Miller Fisher Syndrome in a Patient With a History of Guillain-Barré Syndrome: A Case Report

Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies

How Does SARS-CoV-2 Affect Our Eyes—What Have We Learnt So Far about the Ophthalmic Manifestations of COVID-19?

Contact Info

Product

Resources

About